Multinational pharma firms Novo Nordisk A/S, Sanofi and Eli Lilly and Company have been hit hard in China’s first volume-based tender program for insulin products, amid deep slashes in prices and tender volumes, according to a report published by Chinese brokerage firm CITIC Securities on 29 November.
On 26 November, the three companies, along with eight Chinese domestic insulin makers, participated in a tender program organized by...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

